On the stock market since 1994, it operates in the world of health and science. It has 580 employees. Now — the numbers.
This is an established company with proven profits.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
Average growth of 54% a year over the last 4 years. Red columns mark years that ended in a loss.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Profit indicators sit around the sector average.
A solid grade overall — yet the debt outweighs the cash. The strength here comes from earnings power.
The price isn’t cheap next to earnings — that’s why this grade sits in the middle.
Clearly above the class average — a step short of the very top.
No real weak spot in any of the five subjects — a balanced report card.
angles, checked one by one.
The 2 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
The stock trades 51% below its peak. The market has trimmed its expectations for the company.
The net profit margin is 30% — that slice of every sale is the company’s cushion in hard quarters.
Over the last 3 years, sales grew about 48% a year on average.
Over the last 12 months, company executives reported 51 buys and 26 sells. Management buying with its own money is usually read as a good sign.
Nothing in the current numbers stands out as a clear risk. Still, no stock is ever risk-free.
On our five-subject report card, BCRX sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: BCRX is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s what that quality should cost.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.
Analysts’ average target sits above today’s price, yet the valuation grade (55/100) says the stock isn’t cheap.